Epidemiology of NENs and miRNA-224/LDL-C Level as an Independent Risk Factor in Jiangsu People’s Hospital Abstract #1355

Introduction: Studies show an increasing incidence trend in the neuroendocrine neoplasms(NENs).However,diagnosis and treatment of NENs are still big challenges.It has not been realized that deficiency of serum low density lipoprotein cholesterol(LDL-C) is a risk factor of NENs.
Aim(s): To investigate incidence trends of NENs in Jiangsu People’s Hospital and uncover the role of LDL-C on NENs.
Materials and methods: The data of 164 patients with NENs were retrospectively analyzed. Human pancreatic NENs cell line BON-1 was used to explore the role of miR-224/LDL-C/glucocorticoid(GC) on NENs.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Jian'An Bai
Keywords: NEN, miR-224, LDL-C, survival

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2031 Screening of Differentially Expressed Genes in Gastric Neuroendocrine Neoplasms Based on Human Transcriptome Array
Introduction: Gastric neuroendocrine neoplasms (g-NENs) are a heterogeneous group of tumors.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Yaling Wei
Authors: Wei Y, Bai J, He N, Hua X, ...
#1161 Comparative Proteomic Analysis of Human Insulinoma and Its Clinical Implications in Pancreatic Neuroendocrine Tumors
Introduction: Insulinoma is the most common functional PNET. Its molecular tumorigenesis is largely unknown and proteomic study on insulinoma has not been reported
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Dr Yuan-Jia Chen
Authors: Qiao X W, Song Y L, Bai C M, Zhu L M, ...
#1570 Peptide Receptor Radionuclide Therapy Prolongs Survival in Neuroendocrine Neoplasms: A Single Centre Study in 1048 Patients over 10 Years
Introduction: Peptide receptor radionuclide therapy (PRRT) of somatostatin receptor (SSTR) expressing neuroendocrine neoplasms (NEN) has shown promising results about progression free survival (PFS) and overall survival (OS) in numerous phase II trials, and also in a recently published randomized controlled prospective phase III study (NETTER-1).
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Harshad Kulkarni
Keywords: PRRT, Survival, PET/CT
#692 Prognostic Factors and Survival in Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors account for 2-3% of all pancreatic neoplasms.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD Raziye B. Cetinkaya
#1044 Trends in Neuroendocrine Tumor in Friuli Venezia Giulia in the Last 20 Years
Introduction: Epidemiological study conducted on patients (pts) with neuroendocrine tumors (NEN) at the regional referral center for Endocrinology and Metabolic Diseases of the Udine Hospital, Italy.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Prof Franco Grimaldi
Keywords: survival